138530-95-7 Usage
Description
(S)-Lansoprazole is a proton pump inhibitor that irreversibly inhibits H+/K+-stimulated ATPase pumps in parietal cells, effectively reducing gastric acid secretion and increasing intragastric pH. It is an enantiomerically pure form of lansoprazole, with both (S)and (R)-lansoprazole being pharmacologically active but with the (S)-form being more potent. It is a light brown solid and is widely used as an antiulcerative agent.
Uses
Used in Pharmaceutical Industry:
(S)-Lansoprazole is used as a gastric proton pump inhibitor for treating conditions associated with excessive gastric acid production, such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. It helps in reducing the symptoms and promoting healing of the affected areas by lowering the acidity in the stomach.
Used in Gastroenterology:
(S)-Lansoprazole is used as an antiulcerative agent for the management of ulcers in the stomach and duodenum. By inhibiting gastric acid secretion, it aids in the healing process and reduces the risk of complications such as bleeding or perforation.
Used in Combination Therapy:
(S)-Lansoprazole is also used in combination with antibiotics for the eradication of Helicobacter pylori, a bacterium that can cause peptic ulcers and increase the risk of gastric cancer. This combination therapy helps in effectively treating the infection and reducing the likelihood of ulcer recurrence.
Check Digit Verification of cas no
The CAS Registry Mumber 138530-95-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,8,5,3 and 0 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 138530-95:
(8*1)+(7*3)+(6*8)+(5*5)+(4*3)+(3*0)+(2*9)+(1*5)=137
137 % 10 = 7
So 138530-95-7 is a valid CAS Registry Number.
InChI:InChI=1/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m0/s1
138530-95-7Relevant articles and documents
Method for preparing dexlansoprazole through catalysis of hexadentate ligand
-
Paragraph 0037; 0039-0040; 0042-0043; 0045; 0055; 0057, (2020/05/30)
The invention belongs to the technical field of chemical engineering, and particularly provides a method for preparing dexlansoprazole through catalysis of a hexadentate ligand. Under the catalysis ofa complex formed by a Ti(O-iPr)4 catalyst and a self-made hexadentate ligand, lansoprazole thioether is subjected to asymmetric oxidation, and dextral lansoprazole is obtained. The hexadentate ligandused in the method is simple to prepare and high in yield, and the complex formed by the hexadentate ligand and the Ti(O-iPr)4 catalyst is high in catalytic efficiency and high in enantiomeric excessvalue.
Preparation of asymmetric phase-transfer catalyst, 1,4-bis((4s,5s)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-ylidene)piperazine-1,4-diium chloride
Ang, Esther Cai Xia,Tan, Choon-Hong,Ye, Xinyi
, p. 274 - 293 (2020/10/12)
-
Enantioselective Separation over a Chiral Biphenol-Based Metal-Organic Framework
Abbas, Anees,Wang, Zhao-Xi,Li, Zijian,Jiang, Hong,Liu, Yan,Cui, Yong
supporting information, p. 8697 - 8700 (2018/08/17)
A chiral porous 3D metal-organic framework (MOF) is constructed from an enantiopure carboxylate ligand of 1,1′-biphenol, which can be utilized as adsorbent for the separation of aromatic alcohols and sulfoxides with enantioselectivity of up to 99.4%. Single-crystal X-ray diffraction analysis reveals the binding sites and host-guest interactions clearly, providing microscopic insight into the origin of the enantiosorption in the framework.